Skip to main content
Clinical Trials/NL-OMON52942
NL-OMON52942
Completed
N/A

Study on the potential pharmacokinetic interaction between cannabidiol (CBD) and tamoxifen in patients with primary breast cancer - The TUCAN study

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
26
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \>\= 18 years
  • 2\. WHO performance \<\= 1
  • 3\. Patients with primary breast cancer, who are on adjuvant tamoxifen treatment
  • and are willing to be treated with tamoxifen for at least 2 more months
  • 4\. Patients need to be on a steady state endoxifen level of at least 16 nmol/l
  • 5\. Patients need to experience at least one of the following tamoxifen\-related
  • side effects (based on the CTCAE version 5\.0\)
  • a. Hot flashes: at least \>10 hot flashes during 24 hours and moderate (limited
  • instrumental ADL) or severe (limited self\-care ADL)
  • b. Insomnia: difficulty falling asleep, staying asleep or waking up early

Exclusion Criteria

  • 1\. Patients with known impaired drug absorption (e.g. gastrectomy and
  • achlorhydria)
  • 2\. Known serious illness or medical unstable conditions that could interfere
  • with this study requiring treatment (e.g. HIV, hepatitis, Varicella zoster or
  • herpes zoster, organ transplants, kidney failure (GFR\<30 ml/min/1\.73 m2\),
  • serious liver disease (e.g. severe cirrhosis), cardiac and respiratory diseases)
  • 3\. Use of cannabinoids in the last 3 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials